Mobilising Electric Vehicle Financing in India

• NITI Aayog and Rocky Mountain Institute (RMI) India released a new report ‘Mobilising Electric Vehicle Financing in India’, which highlights the role of finance in India’s transition to electric vehicles (EVs) and analyses that the transition will require a cumulative capital investment of USD 266 billion (Rs 19.7 lakh crore) in EVs, charging infrastructure, and batteries over the next decade.
• The report also identifies a market size of USD 50 billion (Rs 3.7 lakh crore) for the financing of EVs in 2030—about 80% of the current size of India’s retail vehicle finance industry, worth USD 60 billion (Rs 4.5 lakh crore) today.
• India’s EV ecosystem has thus far focused on overcoming adoption hurdles associated with technology cost, infrastructure availability, and consumer behaviour.
• Financing is the next critical barrier that needs to be addressed to accelerate India’s electric mobility transition.
• To address these challenges, NITI Aayog and RMI have identified a toolkit of 10 solutions that financial institutions such as banks and non-banking financial companies (NBFCs), as well as the industry and government, can adopt in catalysing the required capital.
• The 10 solutions recommended in the report include financial instruments such as priority-sector lending and interest-rate subvention. Others are related to creating better partnerships between OEMs and financial institutions by providing product guarantees and warranties. Furthermore, a developed and formal secondary market can improve the resale value of EVs and improve their bankability.
• Recommendations beyond finance include digital lending, business model innovation, fleet and aggregator electrification targets, and the creation of an open data repository for EVs.
• The report further determines that investment in India’s transition to electric mobility has the potential to create significant economic, social, and environmental benefits for the country.
• As the economics of EVs continue to improve, new business models and financing instruments gain acceptance, and government programmes drive early adoption and promote domestic manufacturing, India’s EV market is poised for growth in the coming decade.

National AYUSH Mission

• Ministry of AYUSH, Government of India is implementing Centrally Sponsored Scheme of National AYUSH Mission (NAM).
• Under ‘Medicinal Plants’ component of the NAM scheme supporting market driven cultivation of prioritized medicinal plants in identified cluster/zones with in selected districts of States and implemented in a mission mode.
• As per the scheme guidelines, the support is provided for:
  1. Cultivation of prioritized medicinal plants on farmer’s land.
  2. Establishment of nurseries with backward linkages for raising and supply of quality planting material.
  3. Post-harvest management with forward linkages.
  4. Primary processing, marketing infrastructure etc.

• Under this scheme, subsidy @30%, 50% and 75% of cultivation cost of specific plant species is provided for cultivation of 140 medicinal plants.  

Other missions for AYUSH

• National Medicinal plants Board, Ministry of AYUSH, Government of India is also implementing Central Sector Scheme on “Conservation, Development and Sustainable Management of Medicinal Plants” wherein following activities are supported:
  1. In-situ conservation / Ex-situ conservation
  2. Livelihood linkages with Joint Forest Management Committees (JFMCs) / Panchayats / Van Panchayats / Biodiversity Management Committees (BMCs) / Self Help Groups (SHGs).
  3. IEC activities like Training / workshops / Seminars/ Conferences etc.
  4. Research & Development.
  5. Promotion, marketing and trade of medicinal plants produce.

• Ministry of Finance has announced Rs. 4000 crore package under Atma Nirbhar Bharat for Promotion of Herbal Cultivation.
• The Ministry of AYUSH has prepared a draft scheme namely “Pradhan Mantri VRIKSH AYUSH Yojana” for cultivation and marketing of medicinal plants which is yet to be approved from Cabinet. The scheme will be implemented throughout the country.

Anti-microbial resistance crisis in India

What is Antimicrobial resistance?

• Antimicrobial resistance (AMR or AR) is the ability of a microbe to resist the effects of medication that once could successfully treat the microbe.
• In other words, Antimicrobial resistance (AMR) is the ability of a microorganism (like bacteria, viruses, and some parasites) to stop an antimicrobial (such as antibiotics, antivirals and antimalarials) from working against it.
• As a result, standard treatments become ineffective, infections persist and may spread to others.
• When an organism is resistant to more than one drug, it is said to be multidrug-resistant. Then

What is Antibiotic resistance?

• The term antibiotic resistance is a subset of AMR, as it applies only to bacteria becoming resistant to antibiotics.
• Antibiotics are medicines used to prevent and treat bacterial infections. Antibiotic resistance occurs when bacteria change in response to the use of these medicines.
• Bacteria, not humans or animals, become antibiotic-resistant.
• These bacteria may infect humans and animals, and the infections they cause are harder to treat than those caused by non-resistant bacteria.
• Antibiotic resistance occurs naturally, but misuse of antibiotics in humans and animals is accelerating the process.
• A growing number of infections – such as pneumonia, tuberculosis, gonorrhoea, and salmonellosis – are becoming harder to treat as the antibiotics used to treat them become less effective.
• It leads to higher medical costs, prolonged hospital stays, and increased mortality.

Key findings:

1. India is one of the top users of antibiotics.
2. The private sector clocked high levels of antibiotic prescription rates (412 per 1,000 persons per year).
3. The highest rate was seen among children aged 0–4 years (636 per 1,000 persons) and the lowest in the age group 10–19 years (280 per 1,000 persons).
4. Per-capita antibiotic consumption in the retail sector has increased by around 22% in five years from 2012 to 2016.

Ways by which individuals become antibiotic-resistant (2019 PT)

• Inappropriate use of antibiotics such as popping pills for mild ailments like the common cold.
• Rampant use of antibiotics in livestock and poultry animals. Antibiotics used in animals to treat infections and for growth promotion are often passed on to humans who consume their meat.
• Improper disposal of residual antibiotics that eventually enter the food chain.
• Prolonged illness
• Poor diagnosis
• Poor health and hygiene management in Hospitals (Fluid exchange)
• Globalisation

Doctors’ take on antibiotics

• Doctors believe that the inappropriate and sometimes rampant use of antibiotics has transformed the healthy human intestinal gut flora into a reservoir of antibiotic resistance organisms.
• At present organisms are resistant to low end antibiotics but if the misuse persists, these may become resistant to high end antibiotics as well.
• There are as many bacteria in a human body as the number of cells. They perform a host of functions to keep the body running for example, processing the food we eat and modulating the immune system. The antibiotic-resistant bacteria aren’t healthy so they cannot perform these functions well.
• The presence of antibiotic resistance in healthy individuals is a cause for concern because it signals that it will get more difficult to treat infections in the future.

India’s action plan for AMR

• A national policy for containment of AMR was introduced in 2011. The policy aims to understand emergence, spread and factors influencing AMR.
• To set up an antimicrobial program to rationalize use of antimicrobials and to encourage the innovation of newer and effective antimicrobials.
• In addition, some major action points identified in the national policy are:
  1. Establishing an AMR surveillance system.
  2. To strengthen infection, prevention and control measures.
  3. Educate, train and motivate all stakeholders in the rational use of antimicrobials.
  4. Providing sanitation, clean water and good governance.
  5. Increasing public health expenditure and better regulating the private health sector.

WHO’s take on antibiotic resistance?

• As per the World Health Organization (WHO), antibiotic resistance is rising to dangerously high levels in all parts of the world.
• The alarming rate at which bacteria are becoming resistant has led the World Health Organization (WHO) to identify AMR as one of the top ten threats to global health.
• The world body recommends that countries must prioritize their national action plans to scale up financing and capacity-building efforts, put in place stronger regulatory systems and support awareness programmes for responsible and prudent use of antimicrobials by professionals in humans, animals and plants health.
• In addition, countries must invest in ambitious research and development technologies to combat AMR.
• The WHO also suggests a number of steps that can be taken at various levels to reduce the impact and also limit the spread of this resistance.

At individual level

• For individuals, the most important step toward preventing and controlling the spread of this antibiotic resistance is to use antibiotics only when prescribed by a certified health professional. Also, never shared with anyone who used leftover antibiotics.
• Preparing food hygienically and avoiding close contact with sick people.
• Practising safer sex and keeping vaccinations up to date.
• Following the WHO’s five keys to safer food i.e. to keep clean, separate raw and cooked, cook thoroughly, keep food at safe temperatures, use safe water and materials and choose foods that have been produced without the use of antibiotics for growth promotion or disease prevention in healthy animals.

For Policymakers

• Policymakers must ensure that a robust national action plan is in place to tackle antibiotic resistance.
• Surveillance of antibiotic-resistant infections must be improved.
• Policies, programmes and implementation of infection prevention and control measures must be strengthened.
• It is required to regulate and promote the appropriate use of quality medicines.
• The information must also be made available on the impact of antibiotic resistance.

For Health Professionals

• Health professionals need to play a major role in preventing and controlling the spread of antibiotic resistance.
• The first and foremost thing that must be done is to ensure that their hands, instruments and environment are clean.
• They should only prescribe and dispense antibiotics when they are needed.
• They must immediately report antibiotic-resistant infections to surveillance teams.

For different sectors

• Sectors like healthcare and agriculture must also act to prevent and control the spread of antibiotic resistance.
• The healthcare industry can invest in research and development of new antibiotics, vaccines, diagnostics and other tools.
• The agricultural sector must adhere to the guidelines such as giving antibiotics to animals only under veterinary supervision.
• Antibiotics should not be used for growth promotion or to prevent diseases in healthy animals.
• Animals must be vaccinated to reduce the need for antibiotics and use alternatives to antibiotics when available.
• The agriculture sector should also promote and apply good practices at all steps of production and processing of food from animals and plant sources.
• In addition, they must also improve biosecurity on farms and prevent infections through improved hygiene and animal welfare.

Global Efforts for Anti-microbial resistance:

GLASS (Global Antimicrobial Surveillance System)

• In 2015, WHO launched the global antimicrobial surveillance system (GLASS) to work closely with WHO collaborating centres and existing antimicrobial resistance surveillance networks.

• As members of GLASS, countries are encouraged to implement the surveillance standards and indicators gradually based on their national priorities and available resources.

• Recently, the United Nations (UN) has begun considering the threat of antimicrobial resistance (AMR) to be at par with diseases like ebola, HIV.
• The WHO has launched a global campaign that urges countries to adopt its new online tool aimed at guiding policy-makers and health workers to use antibiotics safely and more effectively.

AWARE Tool by WHO

The tool, known as ‘AWaRe’, classifies antibiotics into three groups:

• Access — antibiotics used to treat the most common and serious infections
• Watch — antibiotics available at all times in the healthcare system
• Reserve — antibiotics to be used sparingly or preserved and used only as a last resort

Collistin

• India has been called the epicenter of the global drug resistance crisis. Chickens in numerous poultry farm are being given Colistin, to protect them against diseases or to make them gain weight faster. Doctors call Colistin the ‘last hope’ antibiotic.
• The World Health Organisation has called for the use of such antibiotics to be restricted to animals. These should be banned as growth promoters.
• MCR-1 is one such gene discovered recently. It could be transferred within and between species of bacteria. This means that microbes did not have to develop resistance themselves, they could become resistant just by acquiring the MCR-1 gene.
• The resistance could be passed to bugs which are already multi-drug resistant. This could lead to untreatable infections.
• Another such gene is New Delhi Metallo-beta-lactamase 1 (NDM-1), which makes bugs resistant to carbapenem antibiotics.

Why is resistance among microbes a problem?

1. The answer lies in the intimacy shared between environmental bacteria and human pathogens
2. A pathogen, say Klebsiella pneumoniae (K. pneumoniae), that causes pneumonia, can take two routes to antibiotic resistance
3. The first is for its own genes to mutate spontaneously to help fight the drug
4. The second route, a shortcut known as horizontal gene transfer, is for the bug to borrow resistance genes from its neighbours
5. Scientists believe that many human pathogens today picked up their resistance genes from the environment through this shortcut

Phenomenon of anti-microbial resistance not new

1. Phylogenetic studies suggest that the earliest antibiotic-resistance genes in nature are millions of years old
2. But when humans started manufacturing antibiotics in the 1950s, a dramatic shift occurred
3. Large doses of these drugs seeped into the environment through poultry and human excreta, and waste water from drug makers and hospitals
4. This led to an explosion of resistance genes in soil and water microbes

European project ANSWER

• It stands for ‘Antibiotics and mobile resistance elements in wastewater reuse applications: risks and innovative solutions’. This project studies technologies to remove antibiotic-resistance germs from wastewater along with other research.

How is the Anti microbial resistance spread?

How to stop the spread of Anti microbial resistance?

India’s Efforts for Anti-microbial resistance

National Action Plan on Antimicrobial Resistance, 2017

1. For the first time, the 2017 National Action Plan on Antimicrobial Resistance talks about limiting antibiotics in effluent being dumped by drug makers into the environment
2. This is because when these drugs taint soil and water, the scores of microbes that live there grow drug-resistant
3. Until now, India’s fight against antibiotic-resistance was focussed on getting people to cut down on unnecessary antibiotic consumption

India’s Red line campaign:

• It was launched in Feb 2016 and is finding recognition, and could be adopted globally. It should be considered as starting point of restriction over use of antibiotics.
• Aim: To decrease the use of Red line antibiotics without prescription, create awareness of danger of taking antibiotics.

Global Antimicrobial Resistance R&D Hub

• Recently, India has joined the Global Antimicrobial Resistance (AMR) Research and Development (R&D) Hub as a new member.
• Working with AMR(R&D) Hub would help India to expand existing capabilities, resources and collectively focus on new R&D intervention to address drug-resistant infections present in the country.
• Global Antimicrobial Resistance (AMR) Research and Development (R&D) Hub is a collaboration of 16 countries, the European Commission, two philanthropic foundations and four international organizations (as observers).
• It was launched in 2018 during the 71st session of the World Health Assembly, following a call from G20 Leaders in 2017.
• It is supported through a Secretariat, established in Berlin, Germany.
• It aims to further improve the coordination of international efforts and initiatives to tackle Antimicrobial Resistance while further increasing investments into R&D for AMR.
• The work of the Global AMR R&D Hub will be aligned to the priorities set by
  1. World Health Organization (WHO)
  2. Food and Agriculture Organization of the United Nations (FAO)
  3. World Organisation for Animal Health (OIE).
• It enforces the One Health Approach by including environmental aspects and veterinary medicine against antimicrobial resistance.
• It integrates human and animal health, worldwide food safety and environmental factors.

Other Steps to fight against AMR

• Infection control in healthcare facilities.
• Creating awareness about the use and abuse of antibiotics.
• Vaccination can combat drug resistance by reducing the cases of infection and as a result reducing the need for antibiotics.
• Strengthening resistance tracking so that data on antimicrobial resistant infections and causes of infection can be gathered to enable formulation of specific strategies to prevent the spread of the resistant bacteria.
• Self-medication should be shunned.
• Antibiotics should be used only when prescribed by the doctor.
• Appropriate and safe use of antibiotics- taking antibiotics only when needed, choosing the right antibiotic and completing the full prescription.
• Invest in the search for new antibiotics to keep up with resistant bacteria as well as in new diagnostic tests to track the development of resistance.

Impacts of Anti-Microbial resistance

• A threat to prevention and treatment of infections - medical procedures such as organ transplantation, cancer chemotherapy, diabetes management and major surgery (for example, caesarean sections or hip replacements) become very risky.
• The failure to treat infections caused by resistant bacteria also poses a greater risk of death.
• Antimicrobial resistance increases the cost of health care with lengthier stays in hospitals, additional tests and use of more expensive drugs.
• Without effective antibiotics for prevention and treatment of infections, the achievements of modern medicine are put at a risk.
• Without urgent action, we are heading to antibiotic apocalypse – a future without antibiotics, with bacteria becoming completely resistant to treatment and when common infections and minor injuries could once again kill.
• Antimicrobial resistance is putting the gains of the Millennium Development Goals at risk and endangers achievement of the Sustainable Development Goals.

Shortcomings in fighting AMR

• A cross-cutting programme dealing with antimicrobial resistance across multiple microbes has been lacking.
• Absence of a One Health Approach in addressing AMR – which recognizes that human well-being is inextricably tied to the health of animals and the environment.
• The absence of stringently framed and implemented regulatory frameworks to limit the use of antimicrobials in livestock and food animals, especially for non-therapeutic purposes, has been one of the drivers of antibiotic overuse at the community level.
• In India, current effluent standards do not include antibiotic residues, and thus they are not monitored in the pharmaceutical industry effluents.

Way Forward

• AMR has the potential to return the world to a pre-antibiotic era when medicines could not treat even simple infections.
• Therefore, to contain AMR, there is need for a One Health Approach through coherent, integrated, multi sectoral cooperation and actions, as human, animal and environmental health are integrated.
• Development of antibiotic resistance breakers (ARBs) to restore effectiveness of older classes of antibiotics.

Conclusion

• Antibiotic resistance is not a problem that can be solved by any one country or even one region. Since, we live in a connected world, where people, animals and food travel and microbes travel with them, a global action is essential to make progress in the long run.
• Increasing public awareness and understanding is therefore the most crucial pillar towards tackling antimicrobial resistance.
• AMR is an increasingly serious threat to the global public health that requires action across all government sectors and societies.